BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28777492)

  • 1. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
    Sakurai T; Yada N; Hagiwara S; Arizumi T; Minaga K; Kamata K; Takenaka M; Minami Y; Watanabe T; Nishida N; Kudo M
    Cancer Sci; 2017 Oct; 108(10):1996-2003. PubMed ID: 28777492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Oncoprotein Gankyrin/PSMD10 as a Target of Cancer Therapy.
    Fujita J; Sakurai T
    Adv Exp Med Biol; 2019; 1164():63-71. PubMed ID: 31576540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3.
    Sakurai T; Higashitsuji H; Kashida H; Watanabe T; Komeda Y; Nagai T; Hagiwara S; Kitano M; Nishida N; Abe T; Kiyonari H; Itoh K; Fujita J; Kudo M
    Oncotarget; 2017 Apr; 8(15):24762-24776. PubMed ID: 28160571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
    Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
    Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
    Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF
    Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
    Li R; Yanjiao G; Wubin H; Yue W; Jianhua H; Huachuan Z; Rongjian S; Zhidong L
    Oncotarget; 2017 Mar; 8(12):19354-19364. PubMed ID: 28423613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
    Hung MH; Tai WT; Shiau CW; Chen KF
    World J Gastroenterol; 2014 Nov; 20(41):15269-74. PubMed ID: 25386075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
    Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.
    Liu R; Li Y; Tian L; Shi H; Wang J; Liang Y; Sun B; Wang S; Zhou M; Wu L; Nie J; Lin B; Tang S; Zhang Y; Wang G; Zhang C; Han J; Xu B; Liu L; Gong K; Zheng T
    Cancer Lett; 2019 Feb; 443():34-46. PubMed ID: 30503555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
    J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Tai WT; Shiau CW; Chen HL; Liu CY; Lin CS; Cheng AL; Chen PJ; Chen KF
    Cell Death Dis; 2013 Feb; 4(2):e485. PubMed ID: 23392173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
    Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
    Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
    Tai WT; Shiau CW; Li YS; Chen YL; Chu PY; Huang JW; Hsu CY; Hsu YC; Chen PJ; Chen KF
    Mol Cancer Ther; 2014 Jan; 13(1):27-36. PubMed ID: 24275147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
    World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
    Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
    J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.